Perrigo (PRGO) Cost of Revenue (2012 - 2026)
Perrigo's (PRGO) quarterly Cost of Revenue came in at $22.6 million in Q1 2026, down 96.53% year-on-year from $651.6 million in Q1 2025, and up 101.18% on a QoQ basis from -$1.9 billion in Q4 2025.
Perrigo (PRGO) Cost of Revenue (2012 - 2026) Analysis & Trends
Perrigo (PRGO) has 15 years of Cost of Revenue data on file, last reported at $22.6 million in Q1 2026.
- On a quarterly basis, Cost of Revenue fell 96.53% year-over-year to $22.6 million in Q1 2026; TTM through Mar 2026 was -$1.2 billion, a 262.49% decrease from a year earlier, with the FY2025 full-year figure at $93.4 million, down 4.69% from the prior year.
- Cost of Revenue for Q1 2026 stood at $22.6 million, up from -$1.9 billion in the prior quarter.
- Over the last five years, Cost of Revenue for PRGO reached as high as $765.1 million in Q3 2023 and fell as low as -$2.1 billion in Q4 2022.
- Historically, Cost of Revenue has averaged -$10.3 million across 5 years, with a median of $25.5 million in 2023.
- Across the five-year window, Cost of Revenue surged 3310.65% in 2022 and slumped 8330.9% in 2025, its largest moves.
- Year by year, Cost of Revenue stood at -$2.1 billion in 2022, then surged by 101.21% to $25.5 million in 2023, then declined by 8.63% to $23.3 million in 2024, then slumped by 8330.9% to -$1.9 billion in 2025, then jumped by 101.18% to $22.6 million in 2026.
- Per Business Quant data, the three most recent Cost of Revenue figures were $22.6 million in Q1 2026, -$1.9 billion in Q4 2025, and $24.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 2.01 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 641.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 2.59 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 133.40 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 2.36 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 13.80 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 586.00 Mn |
| 10 | Perrigo | 1.42 Bn | 1.06 Bn | 325.50 Mn | 22.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 22.60 Mn |
| Mar 28, 2026 | 22.60 Mn |
| Dec 31, 2025 | -1.92 Bn |
| Dec 31, 2025 | -1.92 Bn |
| Sep 27, 2025 | 24.20 Mn |
| Sep 27, 2025 | 24.20 Mn |
| Jun 28, 2025 | 693.40 Mn |
| Jun 28, 2025 | 693.40 Mn |
| Mar 29, 2025 | 651.60 Mn |
| Mar 29, 2025 | 651.60 Mn |
| Dec 31, 2024 | 23.30 Mn |
| Dec 31, 2024 | 23.30 Mn |
| Sep 28, 2024 | 25.20 Mn |
| Sep 28, 2024 | 25.20 Mn |
| Jun 29, 2024 | 24.60 Mn |
| Jun 29, 2024 | 24.60 Mn |
| Mar 30, 2024 | 24.90 Mn |
| Mar 30, 2024 | 24.90 Mn |
| Dec 31, 2023 | 25.50 Mn |
| Dec 31, 2023 | 25.50 Mn |